当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
Wilate, von Willebrand Factor/Coagulation Factor VIII Complex (Human)
申请企业
Octapharma Pharmazeutika Produktionsges.m.b.H.
药品名称
Wilate, von Willebrand Factor/Coagulation Factor VIII Complex (Human)
承诺描述
Deferred pediatric study under PREA for the treatment of hemophilia A in pediatric patients 1less than 12 years of age (WIL-30). Final Protocol Submission: June 19, 2017 Study Completion Date: March 30, 2019 Final Report Submission: December 31, 2019
承诺状态描述
The final report was submitted to FDA on December 18, 2019